Cargando…
How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes
SIMPLE SUMMARY: TP53 mutations are seen in 5–10% of de novo MDS and AML, but 25–40% of therapy-related MDS and AML. Despite the addition of recent drugs to the common regimen and improvement of post transplantation survival, these particular myeloid malignancy subtypes remain a challenge for hematol...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496940/ https://www.ncbi.nlm.nih.gov/pubmed/36139679 http://dx.doi.org/10.3390/cancers14184519 |